A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
NCT ID: NCT03403790
Last Updated: 2024-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
369 participants
OBSERVATIONAL
2018-01-15
2020-03-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quetiapine Fumarate Bipolar Maintenance Monotherapy
NCT00314184
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
NCT01256177
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
NCT01725282
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
NCT02362412
Oral Multiple-dose Study in Patients With Major Depressive Disorder
NCT01924520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with depression in bipolar disorder
Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
Quetiapine
Oral (extended-release tablet)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine
Oral (extended-release tablet)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have previously not been treated with quetiapine fumarate (immediate-release formulations of quetiapine fumarate and Bipresso Extended-Release Tablets)
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site JP00023
Aichi, , Japan
Site JP00005
Akita, , Japan
Site JP00002
Aomori, , Japan
Site JP00012
Chiba, , Japan
Site JP00038
Ehime, , Japan
Site JP00018
Fukui, , Japan
Site JP00040
Fukuoka, , Japan
Site JP00007
Fukushima, , Japan
Site JP00021
Gifu, , Japan
Site JP00010
Gunma, , Japan
Site JP00034
Hiroshima, , Japan
Site JP00001
Hokkaido, , Japan
Site JP00028
Hyōgo, , Japan
Site JP00008
Ibaraki, , Japan
Site JP00017
Ishikawa, , Japan
Site JP00037
Kagawa, , Japan
Site JP00046
Kagoshima, , Japan
Site JP00014
Kanagawa, , Japan
Site JP00039
Kochi, , Japan
Site JP00043
Kumamoto, , Japan
Site JP00026
Kyoto, , Japan
Site JP00024
Mie, , Japan
Site JP00004
Miyagi, , Japan
Site JP00045
Miyazaki, , Japan
Site JP00020
Nagano, , Japan
Site JP00042
Nagasaki, , Japan
Site JP00029
Nara, , Japan
Site JP00015
Niigata, , Japan
Site JP00003
Numakunai, , Japan
Site JP00033
Okayama, , Japan
Site JP00047
Okinawa, , Japan
Site JP00027
Osaka, , Japan
Site JP00044
Ōita, , Japan
Site JP00041
Saga, , Japan
Site JP00011
Saitama, , Japan
Site JP00025
Shiga, , Japan
Site JP00032
Shimane, , Japan
Site JP00022
Shizuoka, , Japan
Site JP00009
Tochigi, , Japan
Site JP00036
Tokushima, , Japan
Site JP00013
Tokyo, , Japan
Site JP00031
Tottori, , Japan
Site JP00016
Toyama, , Japan
Site JP00030
Wakayama, , Japan
Site JP00006
Yamagata, , Japan
Site JP00035
Yamaguchi, , Japan
Site JP00019
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6949-MA-3199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.